Content area

|
|

Malignt pleuralt mesoteliom

Forfatter(e)

Sajitha Sophia Sritharan1, 2, Jens Lundby Frandsen2, Øyvind Omland3 & Jens Meldgaard Bruun2

1) Lungemedicinsk Afdeling, Aarhus Universitetshospital 2) Medicinsk Afdeling, Regionshospitalet Randers 3) Det Sundhedsvidenskabelige Fakultet, Klinisk Institut, Arbejdsmedicin, Aalborg Universitetshospital Ugeskr Læger 2018;180:V06170439

Reference: 
Ugeskr Læger 2018;180:V06170439
Blad nummer: 
Sidetal: 
2-6
Malignant pleural mesothelioma

Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. The disease is of importance, since the incidence in Denmark is increasing despite cessation of the use of asbestos in the 1980s. MPM has a long latency period, and the first symptom is often dyspnoea, typically caused by pleural effusion. The diagnosis is a challenge, because cytology often is non-conclusive, and thoracoscopy is needed to obtain biopsies for immunohistochemistry. The occupational history is important, since the patients are entitled to compensation. The treatment is often limited to palliation.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Finn Redke | 24/04
2 kommentarer
af Christian Schlütter | 23/04
1 Kommentar
af Frede Simonsen | 20/04
2 kommentarer
af Hans Storm Erichsen | 19/04
1 Kommentar
af Debatred. | 15/04
1 Kommentar
af Martin Bonde Petersen | 15/04
1 Kommentar
af Anne Lisbeth Hoffmann | 15/04
4 kommentarer
af Jørgen Lous | 13/04
9 kommentarer